Definitive HealthcareNASDAQ: DH

Empowering healthcare and life science organizations with faster insights through seamless data sharing Empowering healthcare and life science organizations with faster insights through seamless data sharing

FRAMINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today released its 2023 sustainability report.

Mr. Coop brings more than 30 years of Operations, Product and Revenue Expertise Mr. Coop brings more than 30 years of Operations, Product and Revenue Expertise

Definitive Healthcare (DH) seems to have received some backing after a recent decline, as shown by the formation of a hammer chart. Along with this technical pattern, a consensus among financial experts in boosting earnings projections adds to the possibility of a rebound for the stock in the near future.

Investors who follow Medical Information Systems stocks are probably aware of Definitive Healthcare Corp. (DH) and Privia Health (PRVA). The question is, which of these stocks provides better value for value investors at the moment?

Definitive Healthcare Corp. (DH) Q4 2023 Earnings Call Transcript

FRAMINGHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Strengthening fundamentals: Definitive Healthcare shows steady revenue growth at 10% and expanding adjusted EBITDA margins. CRPO growth is slowing to a controlled rate and stabilizing, which indicates the end of client churn that took place over past 2 years. Valuation outlook: Fair price potential around $9.0, signaling a 25% upside from current $7.18.